ARID1A and cancer: Importantly, given recent advances in determining T cell subpopulations as predictive biomarkers for immunotherapy through the use of single-cell RNA-sequencing technology [76], future studies may be warranted to carefully evaluate the effects of targeting ARID1A on the antitumor T cell response versus other cancer characteristics of the TME at more improved resolution.